Research Progress of Combination Therapy of Apatinib on Tumor
Angiogenesis plays an important role in tumor growth and metastasis, and vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulatory factor in the process of angiogenesis. Apatinib mesylate is a small molecule tyrosine kinase inhibitor developed over ten years in China. At present, ap...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-03-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1059.htm |
| _version_ | 1818506456544051200 |
|---|---|
| author | WU Shan HUA Zhan LI Jianchen ZHOU Jianjun WANG Zai |
| author_facet | WU Shan HUA Zhan LI Jianchen ZHOU Jianjun WANG Zai |
| author_sort | WU Shan |
| collection | DOAJ |
| description | Angiogenesis plays an important role in tumor growth and metastasis, and vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulatory factor in the process of angiogenesis. Apatinib mesylate is a small molecule tyrosine kinase inhibitor developed over ten years in China. At present, apatinib as single agent has been successfully used in the clinical treatment of advanced gastric cancer, non-small cell lung cancer and breast cancer, etc. The combination of apatinib and other anti-tumor therapies often increases the efficacy and reduces side effects at the same time. In this review, the therapeutic effect and mechanism of apatinib combined with other therapies for varies of tumors were briefly summarized, according to recently reported clinical cases and preclinical researches. |
| first_indexed | 2024-12-10T22:04:51Z |
| format | Article |
| id | doaj.art-4162b2054abe4731aa1eccf03481c2f9 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-10T22:04:51Z |
| publishDate | 2019-03-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-4162b2054abe4731aa1eccf03481c2f92022-12-22T01:31:46ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782019-03-0146327528010.3971/j.issn.1000-8578.2019.18.10598578.2019.18.1059Research Progress of Combination Therapy of Apatinib on TumorWU Shan0HUA Zhan1LI Jianchen2ZHOU Jianjun3WANG Zai4College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, ChinaDepartment of General Surgery, China-Japan Friendship Hospital, Beijing 100029, ChinaCollege of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, ChinaResearch Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai 200120, ChinaInstitute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, ChinaAngiogenesis plays an important role in tumor growth and metastasis, and vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulatory factor in the process of angiogenesis. Apatinib mesylate is a small molecule tyrosine kinase inhibitor developed over ten years in China. At present, apatinib as single agent has been successfully used in the clinical treatment of advanced gastric cancer, non-small cell lung cancer and breast cancer, etc. The combination of apatinib and other anti-tumor therapies often increases the efficacy and reduces side effects at the same time. In this review, the therapeutic effect and mechanism of apatinib combined with other therapies for varies of tumors were briefly summarized, according to recently reported clinical cases and preclinical researches.http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1059.htmapatinibvegfr2combination therapyefficacymechanism |
| spellingShingle | WU Shan HUA Zhan LI Jianchen ZHOU Jianjun WANG Zai Research Progress of Combination Therapy of Apatinib on Tumor Zhongliu Fangzhi Yanjiu apatinib vegfr2 combination therapy efficacy mechanism |
| title | Research Progress of Combination Therapy of Apatinib on Tumor |
| title_full | Research Progress of Combination Therapy of Apatinib on Tumor |
| title_fullStr | Research Progress of Combination Therapy of Apatinib on Tumor |
| title_full_unstemmed | Research Progress of Combination Therapy of Apatinib on Tumor |
| title_short | Research Progress of Combination Therapy of Apatinib on Tumor |
| title_sort | research progress of combination therapy of apatinib on tumor |
| topic | apatinib vegfr2 combination therapy efficacy mechanism |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1059.htm |
| work_keys_str_mv | AT wushan researchprogressofcombinationtherapyofapatinibontumor AT huazhan researchprogressofcombinationtherapyofapatinibontumor AT lijianchen researchprogressofcombinationtherapyofapatinibontumor AT zhoujianjun researchprogressofcombinationtherapyofapatinibontumor AT wangzai researchprogressofcombinationtherapyofapatinibontumor |